MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-07-2024
Trevena ROE Ratio 2011-2026 | TRVN
Annual ROE Ratio Trevena
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 526.17 | -344.06 | -79.82 | -28.22 | -82.69 | -74.13 | -207.5 | -131.07 | -35.3 | -50.1 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 526.17 | -344.06 | -50.67 |
Quarterly ROE Ratio Trevena
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -124.06 | -368.69 | -476.4 | -382.35 | -452.34 | -298.88 | -258.65 | -144.84 | -162.56 | -110.3 | -84.11 | -43.25 | -48.58 | -36.2 | -26.68 | -16.81 | -38.24 | -61.39 | -71.0 | -82.69 | -80.47 | -62.78 | -69.59 | -74.13 | -97.43 | -132.83 | -169.42 | -207.5 | -210.79 | -202.75 | -168.31 | -131.07 | -96.08 | -65.34 | -48.83 | -35.3 | -40.16 | -48.4 | -51.94 | -36.7 | -25.93 | 0.5 | 17.82 | 20.04 | 20.04 | 9.27 | 3.53 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.04 | -476.4 | -112.18 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
114.5 | $ 9.13 | -0.76 % | $ 591 M |  USA |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-5.9 | $ 0.91 | 2.42 % | $ 6.69 M | China |
 |
Edesa Biotech
EDSA
|
-311.44 | $ 15.52 | -2.39 % | $ 49.6 M | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
30.9 | $ 22.47 | 1.19 % | $ 3.72 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Fortress Biotech
FBIO
|
13.66 | $ 2.24 | 0.9 % | $ 62.5 M | USA |
 |
Galectin Therapeutics
GALT
|
24.11 | $ 2.26 | 0.22 % | $ 144 M | USA |
 |
Galapagos NV
GLPG
|
-11.44 | $ 28.07 | 0.75 % | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Grifols, S.A.
GRFS
|
9.2 | $ 8.2 | 3.6 % | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
18.24 | $ 31.01 | -0.13 % | $ 1.78 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
ImmuCell Corporation
ICCC
|
-3.84 | $ 8.44 | - | $ 76.2 M | USA |
 |
InflaRx N.V.
IFRX
|
-43.64 | $ 1.95 | -1.77 % | $ 152 M | Germany |
 |
Immuron Limited
IMRN
|
-12.31 | $ 0.83 | 3.44 % | $ 6.55 M |  Australia |
 |
Incyte Corporation
INCY
|
24.9 | $ 98.87 | -0.23 % | $ 19.3 B | USA |
 |
InMed Pharmaceuticals
INM
|
-65.74 | $ 0.71 | 1.28 % | $ 1.74 M |  Canada |
 |
INmune Bio
INMB
|
-195.26 | $ 1.35 | 1.5 % | $ 33.4 M | USA |
 |
Innoviva
INVA
|
23.12 | $ 23.13 | 0.35 % | $ 1.56 B | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 104.54 | 2.92 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Jaguar Health
JAGX
|
286.68 | $ 7.55 | -4.13 % | $ 17.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
4039.99 | $ 26.67 | -0.02 % | $ 1.44 B | Britain |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-41.02 | $ 1.43 | -4.03 % | $ 235 M | France |
 |
Kamada Ltd.
KMDA
|
9.59 | $ 8.15 | 0.49 % | $ 260 M |  Israel |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-132.24 | $ 13.24 | 6.56 % | $ 1.75 B | Australia |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-0.49 | $ 223.98 | -0.39 % | $ 4.1 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 3.22 | 7.69 % | $ 5.3 M | Israel |
 |
Liquidia Corporation
LQDA
|
-154.03 | $ 38.39 | 0.62 % | $ 3.3 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.08 | 0.74 % | $ 436 M | USA |